IBDEI33E ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,49378,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49378,1,3,0)
 ;;=3^Frontotemporal Dementia NEC
 ;;^UTILITY(U,$J,358.3,49378,1,4,0)
 ;;=4^G31.09
 ;;^UTILITY(U,$J,358.3,49378,2)
 ;;=^329916
 ;;^UTILITY(U,$J,358.3,49379,0)
 ;;=G20.^^187^2447^24
 ;;^UTILITY(U,$J,358.3,49379,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49379,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/ Bhv Dstrb
 ;;^UTILITY(U,$J,358.3,49379,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,49379,2)
 ;;=^5003770^F02.81
 ;;^UTILITY(U,$J,358.3,49380,0)
 ;;=G20.^^187^2447^25
 ;;^UTILITY(U,$J,358.3,49380,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49380,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/o Bhv Dstrb
 ;;^UTILITY(U,$J,358.3,49380,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,49380,2)
 ;;=^5003770^F02.80
 ;;^UTILITY(U,$J,358.3,49381,0)
 ;;=G31.01^^187^2447^26
 ;;^UTILITY(U,$J,358.3,49381,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49381,1,3,0)
 ;;=3^Pick's Disease
 ;;^UTILITY(U,$J,358.3,49381,1,4,0)
 ;;=4^G31.01
 ;;^UTILITY(U,$J,358.3,49381,2)
 ;;=^329915
 ;;^UTILITY(U,$J,358.3,49382,0)
 ;;=G23.1^^187^2447^28
 ;;^UTILITY(U,$J,358.3,49382,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49382,1,3,0)
 ;;=3^Progressive Supranuclear Ophthalmoplegia
 ;;^UTILITY(U,$J,358.3,49382,1,4,0)
 ;;=4^G23.1
 ;;^UTILITY(U,$J,358.3,49382,2)
 ;;=^5003780
 ;;^UTILITY(U,$J,358.3,49383,0)
 ;;=E11.21^^187^2448^33
 ;;^UTILITY(U,$J,358.3,49383,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49383,1,3,0)
 ;;=3^Type 2 DM w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,49383,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,49383,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,49384,0)
 ;;=E11.22^^187^2448^31
 ;;^UTILITY(U,$J,358.3,49384,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49384,1,3,0)
 ;;=3^Type 2 DM w/ CKD
 ;;^UTILITY(U,$J,358.3,49384,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,49384,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,49385,0)
 ;;=E11.40^^187^2448^34
 ;;^UTILITY(U,$J,358.3,49385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49385,1,3,0)
 ;;=3^Type 2 DM w/ Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,49385,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,49385,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,49386,0)
 ;;=E11.65^^187^2448^32
 ;;^UTILITY(U,$J,358.3,49386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49386,1,3,0)
 ;;=3^Type 2 DM w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,49386,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,49386,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,49387,0)
 ;;=E11.9^^187^2448^35
 ;;^UTILITY(U,$J,358.3,49387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49387,1,3,0)
 ;;=3^Type 2 DM w/o Complications
 ;;^UTILITY(U,$J,358.3,49387,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,49387,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,49388,0)
 ;;=E03.9^^187^2448^26
 ;;^UTILITY(U,$J,358.3,49388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49388,1,3,0)
 ;;=3^Hypothyroidism
 ;;^UTILITY(U,$J,358.3,49388,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,49388,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,49389,0)
 ;;=N18.1^^187^2448^14
 ;;^UTILITY(U,$J,358.3,49389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49389,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 1
 ;;^UTILITY(U,$J,358.3,49389,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,49389,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,49390,0)
 ;;=N18.2^^187^2448^15
 ;;^UTILITY(U,$J,358.3,49390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49390,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 2
